Obed Ocampo-Valdez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Obed Ocampo-Valdez has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Cárdenas-Ortega
Clínica de Inmunocompromiso por Enfermedades Infecciosas (CIENI), Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas , Mexico City
1 shared publication - Brenda Crabtree-Ramírez
Departamento de Infectologia, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico
1 shared publication - Edgar Pérez-Barragán
Department of Infectious Diseases, Clínica Especializada Condesa Iztapalapa , Mexico City , Mexico
1 shared publication - Estefanía Sienra-Iracheta
Departamento de Infectología, Hospital General Manuel Gea González , Mexico City
1 shared publication - Héctor Rivera-Villegas
Department of Infectious Diseases, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán , Mexico City
1 shared publication - Jaime Federico Andrade Villanueva
Unidad de VIH, Hospital Civil de Guadalajara “Fray Antonio Alcalde”, Guadalajara 44350, Mexico
1 shared publication
Latest Publications
- Open Access
- 1 July 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (7) , ofag387
Penicillin or Ceftriaxone for Neurosyphilis in People With HIV: A Retrospective, Propensity Score–Matched Multicenter Study in Mexico
Background: Neurosyphilis, ocular syphilis, and otosyphilis occur more frequently among people with HIV-1 and are associated with higher morbidity and treatment failure. Intravenous penicillin G remains the standard therapy but requires hospitalization or prolonged intravenous access, creating barriers that are amplified in resource-limited settings facing recurrent penicillin shortages. Ceftriaxone is a potential alternative; however, comparative data in people with HIV are limited. Methods: We conducted a multicenter retrospective cohort study of adults with HIV at 5 public hospitals and 2 outpatient HIV clinics in Mexico (2015–2024). Participants had confirmed neurosyphilis, ocular syphilis, or otosyphilis. Participants received intravenous penicillin G (18–24 million IU/day) or ceftriaxone (1–2 g/day) for 10–14 days. The primary outcome was early serological response (ESR), defined as a ≥4-fold nontreponemal titer decline or seroreversion at 6 months. We performed 1:1 propensity score matching (39 pairs, n = 78), followed by logistic regression in the matched cohort. Results: Of 143 participants, 104 (73%) received intravenous penicillin G and 39 (27%) ceftriaxone. In the matched cohort, ESR occurred in 74.4% of penicillin-treated participants and 71.8% of ceftriaxone-treated participants (odds ratio 0.88, 95% confidence interval .32–2.40; P = .80). The results were consistent across all prespecified sensitivity analyses. Conclusions: In this multicenter cohort of people with HIV diagnosed with neurosyphilis, ocular syphilis, or otosyphilis, ceftriaxone showed comparable ESR to intravenous penicillin G. These findings support ceftriaxone as a reasonable alternative when standard therapy is limited by penicillin shortages, limited inpatient capacity, or financial constraints.
- 1 July 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (7) , ofag387
Open AccessPenicillin or Ceftriaxone for Neurosyphilis in People With HIV: A Retrospective, Propensity Score–Matched Multicenter Study in Mexico
Background: Neurosyphilis, ocular syphilis, and otosyphilis occur more frequently among people with HIV-1 and are associated with higher morbidity and treatment failure. Intravenous penicillin G remains the standard therapy but requires hospitalization or prolonged intravenous access, creating barriers that are amplified in resource-limited settings facing recurrent penicillin shortages. Ceftriaxone is a potential alternative; however, comparative data in people with HIV are limited. Methods: We conducted a multicenter retrospective cohort study of adults with HIV at 5 public hospitals and 2 outpatient HIV clinics in Mexico (2015–2024). Participants had confirmed neurosyphilis, ocular syphilis, or otosyphilis. Participants received intravenous penicillin G (18–24 million IU/day) or ceftriaxone (1–2 g/day) for 10–14 days. The primary outcome was early serological response (ESR), defined as a ≥4-fold nontreponemal titer decline or seroreversion at 6 months. We performed 1:1 propensity score matching (39 pairs, n = 78), followed by logistic regression in the matched cohort. Results: Of 143 participants, 104 (73%) received intravenous penicillin G and 39 (27%) ceftriaxone. In the matched cohort, ESR occurred in 74.4% of penicillin-treated participants and 71.8% of ceftriaxone-treated participants (odds ratio 0.88, 95% confidence interval .32–2.40; P = .80). The results were consistent across all prespecified sensitivity analyses. Conclusions: In this multicenter cohort of people with HIV diagnosed with neurosyphilis, ocular syphilis, or otosyphilis, ceftriaxone showed comparable ESR to intravenous penicillin G. These findings support ceftriaxone as a reasonable alternative when standard therapy is limited by penicillin shortages, limited inpatient capacity, or financial constraints.